JAK inhibitors and infections risk: focus on herpes zoster

Ther Adv Musculoskelet Dis. 2020 Jun 29:12:1759720X20936059. doi: 10.1177/1759720X20936059. eCollection 2020.

Abstract

Currently, there is a growing interest in Janus kinase (JAK) intracellular signalling since targeted inhibitors against these pathways are proving effective in the treatment of a range of immune-mediated diseases, such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease and atopic dermatitis. In particular, post marketing experience and the increasing development of new pharmacological inhibitors of broad and increasingly selective JAK pathways provide new insights into the JAK pathway role in viral infections as well as their pathogenic role in immune-mediated inflammatory diseases. Herein we provide an overview of the biological role of JAK signalling and its role in immunity against viruses, with particular regard to herpes zoster reactivation. Thereafter, we will discuss the evidence currently available on the principal JAK inhibitors and their association with viral infections.

Keywords: AK; JAK inhibitors; herpes zoster; immune-mediated diseases; inflammatory arthritis; rheumatoid arthritis.